Berkeley, CA · founded 2011
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company in West Berkeley, developing allogeneic (off-the-shelf) CAR-T cell therapies for cancer using its proprietary Cas12a chRDNA editing platform. It was co-founded in 2011 by Rachel Haurwitz (still CEO) and CRISPR pioneer Jennifer Doudna, spun out of UC Berkeley. As a clinical-stage, publicly traded biotech, it carries the usual caveats of the stage: small headcount, revenue that depends on trial readouts and partnerships rather than product sales, and exposure to funding and pipeline risk.
see the full file on Caribou Biosciences| Fertility support | yes |
|---|---|
| 401(k) match | Matches employee contributions up to 4% |
| 401(k) match ceiling | 4% |
| Tuition reimbursement | $2,500 |
| PTO | 15 days |
| Dental | yes |
| Vision | yes |
| Life insurance | yes |
| Disability | yes |
| Mental health | yes |
| FSA (flexible spending account) | yes |
| Commuter benefit | yes |
| Free on-site parking | yes |
| Gym / fitness subsidy | yes |
Every claim above is sourced and dated. See sources on the full page.
Work at Caribou Biosciences and something here is wrong or out of date? Tell us at hello@perks.global and we will check it.